Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a
dismal prognosis. While immunotherapy has been deemed a breakthrough treatment for …

Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface
of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor …

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is
characterized by poor treatment response and low survival time. The current clinical …

Pancreatic cancer (PC) has exceptionally high mortality due to ineffective treatment
strategies. Immunotherapy, which mobilizes the immune system to fight against cancer, has …

Immunotherapy is improving the prognosis and survival of cancer patients, but despite
encouraging outcomes in different cancers, the majority of tumors are resistant to it, and the …

Immunotherapy has made significant strides in cancer treatment, particularly through
immune checkpoint blockade (ICB), which has shown notable clinical benefits across …

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy because of
its aggressive nature and the paucity of effective treatment options. Almost all registered …

As a breakthrough strategy for cancer treatment, immunotherapy mainly consists of immune
checkpoint inhibitors (ICIs) and other immunomodulatory drugs that provide a durable …